Ad
related to: bevacizumab macmillan- Amneal PATHways®
Get resources & services to support
accessibility for patients
- Watch Videos
Hear from Amneal leaders
and tour manufacturing facilities
- Biosimilar FAQs
See FAQs to help you
understand biosimilars
- Biosciences Products
Learn more about our
biosimilar injectables
- Amneal PATHways®
Search results
Results from the WOW.Com Content Network
Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. [30] [28] For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, hepatocellular carcinoma, and renal-cell carcinoma. [31]
Anti–vascular endothelial growth factor therapy, also known as anti-VEGF (/ v ɛ dʒ ˈ ɛ f /) therapy or medication, is the use of medications that block vascular endothelial growth factor.
Therapeutic, diagnostic and preventive monoclonal antibodies are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab.
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer.It is made up of the following drugs: [1] FOL – folinic acid (), a vitamin B derivative with multiple applications, which in this context decreases the cytotoxicity of 5-fluorouracil;
All participants were required to have received bevacizumab. [5] The trial enrolled participants whose tumors were positive for FRα expression as determined by the above assay. [ 5 ] Participants were excluded if they had corneal disorders, ocular conditions requiring ongoing treatment, Grade >1 peripheral neuropathy, or noninfectious ...
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. . It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinas
Sacituzumab govitecan is indicated for the treatment of adults with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease; [11] people with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease; [14] and for people ...
Ad
related to: bevacizumab macmillan